Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HUTCHMED (China) (HCM) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for HUTCHMED (China) (HCM) over the last 12 years, with Q2 2025 value amounting to $46.8 million.

  • HUTCHMED (China)'s Current Deferred Revenue fell 271.85% to $46.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $46.8 million, marking a year-over-year decrease of 271.85%. This contributed to the annual value of -$26.0 million for FY2024, which is 12167.26% down from last year.
  • HUTCHMED (China)'s Current Deferred Revenue amounted to $46.8 million in Q2 2025, which was down 271.85% from $12.7 billion recorded in Q4 2024.
  • HUTCHMED (China)'s Current Deferred Revenue's 5-year high stood at $16.3 billion during Q4 2023, with a 5-year trough of $1.7 million in Q4 2022.
  • Moreover, its 5-year median value for Current Deferred Revenue was $48.2 million (2024), whereas its average is $4.2 billion.
  • As far as peak fluctuations go, HUTCHMED (China)'s Current Deferred Revenue tumbled by 8436.87% in 2022, and later surged by 93999415.71% in 2023.
  • HUTCHMED (China)'s Current Deferred Revenue (Quarter) stood at $11.1 million in 2021, then crashed by 84.37% to $1.7 million in 2022, then skyrocketed by 939994.16% to $16.3 billion in 2023, then fell by 22.12% to $12.7 billion in 2024, then crashed by 99.63% to $46.8 million in 2025.
  • Its Current Deferred Revenue stands at $46.8 million for Q2 2025, versus $12.7 billion for Q4 2024 and $48.2 million for Q2 2024.